Startups
Bioverge Inc
San Francisco, California, USA
Bioverge, Inc. is the Delaware corporate parent of the Bioverge healthcare investment platform, incorporated in August 2017 according to its own issuer campaign; the Bioverge brand and separate fund-management subsidiary began in 2016. Its current own site focuses on early-stage human-health biotechnology, AI-driven drug discovery, neuroscience, genetic medicine, cell therapy, precision medicine and synthetic biology. It gives investors access to deal-specific special-purpose vehicles and diversified access funds. Portfolio and performance statements are the platform’s own commercial claims, not independent clinical or investment-performance validation. The separate wholly owned Bioverge Funds Management LLC manages investment vehicles, while Bioverge Portal LLC has a distinct crowdfunding role. This corporate platform profile does not identify an undisclosed legal SPV as the payer of any branded portfolio investment. The current public about page names Neil Littman as Founder and Managing Partner. Its 2023 Republic offering published sixteen people helping build Bioverge, including external advisers; those dated affiliations are preserved separately without assuming current employment or treating all advisers as employees. Corporate Reg CF financing is separate from cash raised by managed funds. The Republic Crowd SAFE campaign closed August 8, 2023 with USD138,007 from 251 investors. The earlier Netcapital Class B common-stock campaign completed March 1, 2022; its header reports USD708,265, while a March 2 final update calculates USD744,805.89 from shares multiplied by a single price. These inconsistent primary figures are both retained and the earlier round amount remains unknown. Offering maxima, valuation caps, prior aggregate corporate financing and cumulative investment-platform deal volume are not added as new cash rounds.
Founded 2017
Team
Brenden BootExternal Advisor — issuer2023; current tenure unverified |
Brock ReeveExternal Advisor — issuer2023; current tenure unverified |
Curt HerbertsExternal Advisor — issuer2023; current tenure unverified |
Dave ChisholmExternal Advisor — issuer2023; current tenure unverified |
David StubbsExternal Advisor — issuer2023; current tenure unverified |
Greg SimonExternal Advisor — issuer2023; current tenure unverified |
Hollis FulliloveFinance & Accounting — issuer2023; current tenure unverified |
Janine McCargoMedia & PR — issuer2023; current tenure unverified |
Joseph WuExternal Advisor — issuer2023; current tenure unverified |
Kevin CokerExternal Advisor — issuer2023; current tenure unverified |
Luiz FerreiraEngineer & Software Development — issuer2023; current tenure unverified |
Mark ChaoExternal Advisor — issuer2023; current tenure unverified |
 Neil LittmanCo-founder & CEO — issuer2023; current tenure unverified · Founder and Managing Partner — current published Bioverge platform |
 Rick GibbCo-founder & COO — issuer2023; current tenure unverified |
Rishav DasguptaAnalyst — issuer2023; current tenure unverified |
 Sonia ArrisonExternal Advisor — issuer2023; current tenure unverified |
Investments
| $8M2023-06-01 |  Modulo Bio | Cantos, Initialized Capital, Bioverge Inc, Hawktail, Builders VC, Spacecadet Ventures, Refactor Capital |
| $138K2023-08-08 | Bioverge Inc | 0 participations |
| $—2022-03-01 | Bioverge Inc | 0 participations |